Rune Labs bags $12m to advance adoption of Parkinson’s technologies

Neuro software company secures strategic investment from Nexus NeuroTech to accelerate personalized care for Parkinson’s disease.

Precision neurotech company Rune Labs has completed a new funding round, securing $12 million to advance the adoption of its digital technologies targeting Parkinson’s disease. The round, led by a strategic investment from Nexus NeuroTech Ventures, brings the total capital raised by the company to more than $42 million.

“This strategic partnership with Nexus NeuroTech Ventures is in line with our use of modern AI tools to support patients, clinicians, and our pharma partners, and speaks to our ambition to have a deep impact in the way Parkinson’s is understood and treated,” said Brian Pepin, CEO of Rune.

Rune develops precision neurology software and data analytics that support the management of Parkinson’s as well as development of therapies designed to treat the neurodegenerative disease. The company’s StrivePD tool is an iOS disease management app for both patients and clinicians that passively collects daily resting tremor and dyskinesia data via Apple’s Movement Disorder API. The app was granted FDA 510(k) clearance in 2022 and offers curated dashboards that consolidate various patient data sources and connects patients to relevant clinical trials.

“As a person with Parkinson’s disease, I’ve seen the medical community promise new therapies to cure my disease for over a decade,” said Benjamin Stecher, Chair of Rune’s patient advisory board. “Yet, there is still nothing that can slow the progression of these debilitating diseases, which is why we need novel technology to advance our agenda and take us one step closer to finding a cure.”

When it comes to support for Parkinson’s therapeutics development, Rune collaborates with biopharma and medical device companies, providing them with access to its technology, clinician network, and datasets. The company has recently established partnerships with key players in neuroscience, including collaborations with BlueRock Therapeutics and Aspen Neuroscience, which aim to evaluate symptom activity in Parkinson’s clinical trials.

Dr Jordi Parramon, CEO of Nexus NeuroTech Ventures, and former President of Medical Devices at Verily, has been appointed to Rune’s board of directors.

“The future of precision medicine for brain diseases will start with innovative technologies that provide personalized, longitudinal insights into each patient’s unique condition,” said Parramon.

Existing investors also participated in the round, including Eclipse, DigiTx Partners, Moment Ventures, and TruVenturo GmbH.